Physician profile
Page Axley
NPI 1245693613
$2,250.95
in general payments reported to CMS, 2019-2025
21 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.35 · 2022: $162 · 2023: $1,193 · 2024: $523 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.36 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.86 | 2020-2025 | Rinvoq, Linzess, Skyrizi |
| Medtronic, INC. | $273.26 | 2023-2024 | Hawkone |
| Regeneron Healthcare Solutions, INC. | $194.08 | 2023-2024 | Dupixent |
| Genzyme Corporation | $145.01 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $132.72 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $119.25 | 2024 | Voquezna |
| W. L. Gore & Associates, INC. | $98.20 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Celgene Corporation | $92.19 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $90.32 | 2023-2024 | Gattex, Entyvio |
| Gilead Sciences, INC. | $89.25 | 2023 | Epclusa |
| Boston Scientific Corporation | $76.39 | 2023 | |
| Ardelyx, INC. | $59.47 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $58.85 | 2023 | Linzess |
| Janssen Biotech, INC. | $24.66 | 2023 | Stelara |
| Amgen INC. | $21.19 | 2023 | Avsola |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $20.76 | 2023 | Hadlima |
| Ethicon US, LLC | $19.64 | 2025 | Evarrest, Vistaseal, Stratafix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.54 | 2023 | Xifaxan |
| Ossur Americas, INC. | $19.26 | 2025 | |
| Olympus America INC. | $15.35 | 2024 | Evis Exera III Colonovideoscope |
| Redhill Biopharma INC. | $13.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Page Axley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.